Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
AssigneeThe Johns Hopkins University
InventorsSachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
Life of this patent
Estimating the term…
Abstract
The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
Claims26
A nanoparticle composition comprising,
- a) a prostate specific membrane antigen (PSMA) inhibitor;
- b) a linker,
- c) a biologically active agent;
- and
- d) a nanoparticle.
A nanoparticle composition of formula I:
- (X)m(Y)n—Z (I);
- wherein
- X is an organic small molecule PSMA inhibitor;
- Y is an organic linker;
- Z is a nanoparticle comprising a biologically active agent;
- m is 1-1000 and
- n is 1-1000.
7-18. (canceled)
20-30. (canceled)
32-33. (canceled)
35-44. (canceled)
46-49. (canceled)
54-62. (canceled)
Dependencies are inferred from the claim text.